Our drug’s excellent safety profile represents a disruptive advantage over current cancer drugs which are often associated with serious side effects.
Our drug is targeted at treating certain subtypes of the following cancers: leukemia, lymphoma, breast, lung, colorectal, multiple myeloma, melanoma and glioblastoma.
NEW CANCER DRUG KILLS BREAST CANCER, LUNG CANCER, LEUKEMIA AND MELANOMA CELLS
Our developmental-stage cancer drug is essentially free from serious side effects. It’s a breakthrough because it selectively kills cancer cells over normal, healthy cells and is well tolerated by humans. Physicians and patients will prefer it to current, debilitating chemotherapies.
Our study is evaluating the safety and efficacy of pyronaridine as an add-on therapy in adults with acute lymphoblastic leukemia and acute myeloid leukemia. Our study is in countries where pyronaridine is an approved drug for malaria. The primary objective of our study is a comparison of survival lengths between the subjects receiving pyronaridine and placebo.
Powered By Boston SEO Marketing Service